Form 8-K SkinHealth Systems Inc. For: Jun 10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices)
(Zip Code)
(800 ) 603-4996
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 10, 2026, SkinHealth Systems Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") in a virtual format. At the close of business on April 16, 2026, the record date for the Annual Meeting (the "Record Date"), there were 129,584,184 shares of the Company’s Class A Common Stock, par value $0.0001 per share ("Class A Common Stock") issued and outstanding, which constituted all of the issued and outstanding capital stock of the Company as of the Record Date. At the Annual Meeting, 93,406,914 of the Company’s 129,584,184 outstanding shares of Class A Common Stock entitled to vote as of the Record Date, or approximately 72.08%, were present virtually or represented by proxy, and, therefore, a quorum was present.
The three proposals voted on at the Annual Meeting are more fully described in the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on April 24, 2026 (the "Proxy Statement").
The final voting results on the proposals presented for stockholder approval at the Annual Meeting are as follows:
Proposal No. 1: Election of Nine Directors
The Company’s stockholders elected the nine directors listed below, each to serve for a term of one year, expiring at the Company's 2027 annual meeting of stockholders or until his or her successor is duly appointed or elected and qualified or until his or her earlier death, resignation, or removal from office, as follows:
| Nominees | Votes For | Votes Withheld | Broker Non-Votes | |||||||||||||||||
Brenton L. Saunders | 64,713,062 | 7,259,415 | 21,434,437 | |||||||||||||||||
Pedro Malha | 70,933,549 | 1,038,928 | 21,434,437 | |||||||||||||||||
| E. Scott Beattie | 61,017,737 | 10,954,740 | 21,434,437 | |||||||||||||||||
| Stephen J. Fanning | 68,732,826 | 3,239,651 | 21,434,437 | |||||||||||||||||
Michelle Kerrick | 70,684,772 | 1,287,705 | 21,434,437 | |||||||||||||||||
| Brian Miller | 56,555,107 | 15,417,370 | 21,434,437 | |||||||||||||||||
| Doug Schillinger | 61,107,166 | 10,865,311 | 21,434,437 | |||||||||||||||||
| Sachin Shridharani, M.D. | 71,317,162 | 655,315 | 21,434,437 | |||||||||||||||||
| Kenneth Tripp | 71,078,056 | 894,421 | 21,434,437 | |||||||||||||||||
Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent, registered public accounting firm for the fiscal year ending December 31, 2026, as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 93,125,701 | 235,673 | 45,540 | 0 | |||||||||||||||||
Proposal No. 3: Advisory Vote on the Compensation of the Named Executive Officers
The Company’s stockholders approved, on an advisory, non-binding basis, the compensation paid by the Company to its named executive officers as disclosed in the Proxy Statement, as follows:
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||||||||
| 58,604,735 | 12,346,541 | 1,021,201 | 21,434,437 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 16, 2026 | SkinHealth Systems Inc. | |||||||
| By: | /s/ Michael Monahan | |||||||
| Name: | Michael Monahan | |||||||
| Title: | Chief Financial Officer | |||||||
ATTACHMENTS / EXHIBITS
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT